StreetInsider.com News Articles

Verrica Pharma signs Israel deal for skin disease treatment YCANTH

Tue, 21 Jul 2026 08:00:43 -0400

Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has entered into an exclusive distribution, marketing and supply agreement with Medomie Pharma Ltd. to seek regulatory approval for and commercialize YCANTH® in Israel for the treatment of molluscum contagiosum, a contagious viral skin infection.

Under the agreement, Medomie will hold exclusive rights to obtain and maintain marketing authorizations for YCANTH in Israel. Verrica will manufacture and supply the product to Medomie and will receive 60% of the net selling price of product sold in Israel. Verrica is also eligible to receive up to $8.2 million in regulatory and commercial milestone payments.

Jayson Rieger, President and Chief

Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel

Tue, 21 Jul 2026 08:00:00 -0400

WEST CHESTER, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced an exclusive distribution, marketing and supply agreement (“the Agreement”) granting Medomie Pharma Ltd. (“Medomie”) rights to seek regulatory approval for and distribute YCANTH^® for the treatment of molluscum contagiosum (“molluscum”) in Israel.

“We are pleased to partner with Medomie to make YCANTH available in Israel so that more patients have access to treatment for molluscum,” said Jayson Rieger, PhD, MBA, President and Chief

Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel

Tue, 21 Jul 2026 08:00:00 -0400

“We are pleased to partner with Medomie to make YCANTH available in Israel so that more patients have access to treatment for molluscum,” said Jayson Rieger, PhD, MBA, President and Chief

H.C. Wainwright Reiterates Buy Rating on Verrica Pharmaceuticals (VRCA)

Tue, 23 Jun 2026 06:53:17 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $12.00 price target on Verrica Pharmaceuticals (NASDAQ: VRCA).

The analyst commented: "This morning, Verrica Pharmaceuticals announced that the first U.S. patient was dosed in the second clinical trial (COVE-3) in its global Phase 3 program evaluating YCANTH (VP-102) for the treatment of common warts. Verrica’s Japanese development partner, Torii Pharmaceutical Co. Ltd., a wholly-owned subsidiary of Shionogi & Co., Ltd. (4507.T; not rated), announced that the first Japanese patient in the COVE-3 study was dosed last week. An estimated 22M people are afflicted with common warts in the U.S. alone each

Verrica doses first U.S. patient in COVE-3 trial for common warts

Mon, 22 Jun 2026 08:05:15 -0400

Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced that the first U.S. patient has been dosed in COVE-3, the second pivotal clinical trial in its global Phase 3 program evaluating YCANTH (VP-102) for the treatment of common warts.

Torii Pharmaceutical Co. Ltd., Verrica's Japanese development partner and a wholly-owned subsidiary of Shionogi & Co., Ltd., also recently dosed the first Japanese patient in the COVE-3 study. Verrica retains global rights to YCANTH for all indications in all territories outside of Japan.

The Phase 3 program consists of two double-blind, randomized, vehicle-controlled studies evaluating VP-102 applied once every 21 days for up to four applications

Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

Mon, 22 Jun 2026 08:05:00 -0400

– Development Partner Torii Pharmaceutical also recently announced dosing of the first Japanese patient in this trial evaluating YCANTH (TO-208) in Japan –

– Verrica maintains ownership of global rights to YCANTH for all indications in all territories outside of Japan, including common warts –

WEST CHESTER, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that the first U.S. patient was dosed in the second clinical trial (COVE-3) in its

Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

Mon, 22 Jun 2026 08:05:00 -0400

– Development Partner Torii Pharmaceutical also recently announced dosing of the first Japanese patient in this trial evaluating YCANTH (TO-208) in Japan –

– Verrica maintains ownership of global rights to YCANTH for all indications in all territories outside of Japan, including common warts –

Form 4 Verrica Pharmaceuticals For: Jun 05 Filed by: PRYGOCKI MARK A SR